Koizumi, Fumiaki <br/><br/>
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.  [electronic resource] 

 -  International journal of cancer  Jan 2004 
 - 464-72 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>0020-7136 
<br/><br/><label>Standard No.: </label>10.1002/ijc.11539  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>Camptothecin--analogs & derivatives<br/>Cell Division--drug effects<br/>Colorectal Neoplasms--drug therapy<br/>DNA Topoisomerases, Type I--genetics<br/>Drug Interactions<br/>Drug Synergism<br/>Drug Therapy, Combination<br/>Enzyme Inhibitors--therapeutic use<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Gefitinib<br/>Humans<br/>Irinotecan<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Phosphorylation<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Quinazolines--therapeutic use<br/>RNA, Messenger--metabolism<br/>Receptor, ErbB-2--metabolism<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Topoisomerase I Inhibitors<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays